Cerebrolysin vs IDRA-21
A side-by-side research comparison of Cerebrolysin and IDRA-21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | IDRA-21 |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | IDRA-21 (Benzothiadiazide AMPA PAM) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Binds AMPA receptors allosterically, reducing desensitization rates to prolong excitatory currents and facilitate LTP for memory encoding. |
| Molecular weight | <10,000 Da (peptide fraction) | 262.7 Da |
| Half-life | 4-6 hours | 8-12 hours (effects persist 48-72h) |
| Bioavailability | High (IM/IV) | High (oral) |
| Typical dose | 5-30 mL | 10-30 mg |
| Frequency | Daily for 10-20 days | 2-3x per week |
| Route | Intramuscular or IV | Oral |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
IDRA-21 reported benefits
- AMPA receptor potentiation
- Enhanced memory consolidation
- Improved learning speed
- Long-lasting effects
- Oral bioavailability
Related comparisons
Research and educational reference only. Not medical advice.